Zoonotic Disease Treatment Market Forecast to Reach $57.7 Billion by 2030 with 6.2% CAGR

April 8, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Biologics Market During 2026–2030?

The zoonotic disease treatment market has experienced robust expansion in recent years. Its valuation is projected to rise from $42.51 billion in 2025 to $45.48 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.0%. The historical growth can be attributed to frequent zoonotic disease transmission events, limited disease surveillance in animal populations, high dependence on conventional antibiotics, lack of coordinated animal and human health strategies, and increased human-animal interaction.

The zoonotic disease treatment market size is projected to experience significant expansion over the coming years. It is anticipated to grow to $57.77 billion in 2030, achieving a compound annual growth rate (CAGR) of 6.2%. This expected growth during the forecast period can be ascribed to progress in zoonotic disease diagnostics and therapies, increasing acceptance of One Health approaches, greater government financial support for zoonotic disease management, expanding vaccination coverage for animals, and the broadening of global disease surveillance programs. Key trends identified for this period include a rising occurrence of zoonotic disease outbreaks, an intensified focus on preventive treatment and prophylaxis, a growing requirement for broad-spectrum anti-infective treatments, the expansion of integrated animal and human health initiatives, and an emphasis on timely diagnosis and prompt treatment commencement.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15965&type=smp

Which Major Factors Are Driving The Expansion Of The Biologics Market?

A growing requirement for animal proteins is projected to drive the expansion of the zoonotic disease treatment market in the future. These proteins originate from animal sources like meat, dairy products, eggs, and fish, providing all vital amino acids essential for human well-being. This heightened demand for animal proteins stems from factors such as an expanding global population, greater disposable incomes, increasing urbanization, and a heightened understanding of the dietary advantages offered by animal-derived foods. Treatments for zoonotic diseases provide valuable understanding for addressing illnesses linked to animal proteins, deciphering how they spread, creating potent treatments, and putting in place preventative strategies to lessen dangers to public health. As an illustration, data from March 2025, reported by the Australian Bureau of Statistics (ABS) is an Australia-based official national statistical agency, showed a 2.3% increase in per capita consumption of meat and poultry products relative to 2023-24. This clearly indicates a significant rise in the national dietary intake of animal-based protein by weight. Consequently, the escalating demand for animal proteins is propelling the expansion of the zoonotic disease treatment market.

How Are The Various Segments Of The Biologics Market Categorized?

The zoonotic disease treatment market covered in this report is segmented –

1) By Disease Type: Rabies, Tuberculosis, Leishmaniasis, Ebola Virus Disease, Other Disease Types

2) By Drug Class: Anti-Fungal, Anti-Bacterial, Antibiotics, Other Drug Classes

3) By Causative Agent: Bacteria, Virus, Nematode, Rodents, Ticks, Other Causative Agents

4) By Route Of Administration: Oral, Topical, Other Routes Of Administrations

5) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

Subsegments:

1) By Rabies: Post Exposure Prophylaxis (PEP), Pre-Exposure Prophylaxis (PrEP)

2) By Tuberculosis: Latent Tuberculosis Treatment, Active Tuberculosis Treatment

3) By Leishmaniasis: Visceral Leishmaniasis, Cutaneous Leishmaniasis, Mucocutaneous Leishmaniasis

4) By Ebola Virus Disease: Pre-Exposure Vaccination, Post-Exposure Treatment

5) By Other Disease Types: Zika Virus, Lassa Fever, Yellow Fever, Chikungunya

What Trends Are Affecting The Expansion Of The Zoonotic Disease Treatment Market?

Leading companies operating in the zoonotic disease treatment market are channeling their investments into advancing diagnostic capabilities and enhancing treatment protocols. This involves developing sophisticated diagnostic technologies, such as PCR kits, to enable more rapid identification of zoonotic pathogens, along with implementing targeted therapeutic interventions. For instance, in October 2023, BioPerfectus, a China-based biotechnology company focused on diagnostic solutions, introduced thirteen new additions to its Zoonotic Infectious Diseases Total PCR Solution. This expansion aims to strengthen its diagnostic abilities for zoonotic diseases, which represent over 60% of known infectious diseases and 75% of emerging infections. The initiative is designed to improve preparedness and response for health security, especially as climate change aids the spread of infectious diseases to new regions. With these new offerings, the company intends to facilitate quicker diagnoses and better management of zoonotic infections, emphasizing the significance of proactive public health strategies.

Which Major Firms Influence Developments In The Biologics Market?

Major companies operating in the zoonotic disease treatment market are Pfizer Inc., Johnson & Johnson Services Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis International AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Zoetis Inc., Boehringer Ingelheim International GmbH, Elanco Animal Health Incorporated, IDEXX Laboretories Inc., Hikma Pharmaceuticals PLC., Ceva Santé Animale, Vir Biotechnology Inc., Virbac, Vetoquinol S.A., BioCryst Pharmaceuticals Inc, Heska Corporation

Read the full zoonotic disease treatment market report here:

https://www.thebusinessresearchcompany.com/report/zoonotic-disease-treatment-global-market-report

Which Region Currently Holds The Largest Share Of The Biologics Market?

North America was the largest region in the zoonotic disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the zoonotic disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Biologics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15965&type=smp

Browse Through More Reports Similar to the Global Zoonotic Disease Treatment Market 2026, By The Business Research Company

Monkey Pox Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/monkey-pox-treatment-global-market-report

Animal Therapeutics And Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/animal-therapeutics-and-diagnostics-global-market-report

Animal Medicine Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/animal-medicine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795